Medical Resource Utilization for Administration of Trastuzumab in a New Zealand Oncology Outpatient Setting: a Time and Motion Study

Overview

Journal Clinicoecon Outcomes Res

Publisher Dove Medical Press

Specialty Health Services

Date 2015 Aug 8

PMID 26251623

Citations 19

Authors

Richard T North

Vernon J Harvey

Levonne C Cox

Stuart N Ryan

Affiliations

Soon will be listed here.

Abstract

Background: In New Zealand, trastuzumab is standard therapy for human epidermal growth factor receptor-2 (HER2)-positive early and metastatic breast cancer. Given the requirement for ongoing adjuvant or maintenance treatment and intravenous (IV) delivery, such a regimen consumes considerable health care resources. The development of a subcutaneous (SC) trastuzumab formulation with a short administration time offers the potential to reduce hospital expenditure. The aim of this study was to determine medical resource utilization associated with administration of trastuzumab SC injection via handheld syringe vs trastuzumab IV infusion in patients with HER2-positive breast cancer in New Zealand.

Methods: This noninterventional, descriptive study was conducted at the outpatient oncology centers at Auckland City and Tauranga Hospitals. Trained observers recorded times associated with health care professional (HCP) tasks and consumables use associated with preparation and administration of trastuzumab IV or SC in women with early or metastatic breast cancer. The cost for each formulation was calculated as the mean cost of HCP time (based on Pharmaceutical Management Agency hourly rates) plus the mean cost of consumables used.

Results: Use of trastuzumab SC vs IV reduced mean chair time by 36.95 minutes and total nurse time by 6.12 minutes; there was a 20.45-minute reduction in pharmacist time when the SC formulation was used. After adding consumable costs, the overall estimated saving with trastuzumab SC vs IV was $76.94 (New Zealand dollars) per patient per cycle.

Conclusions: Compared with trastuzumab IV infusion, administration of trastuzumab via SC injection reduced time spent in the clinic and decreased HCP resources and consumables needed to administer treatment. These reductions could contribute to a decrease in health care costs and an improvement in the efficiency of HER2-positive breast cancer treatment delivery.

Citing Articles

The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review.

Landeiro L, Martins T, Grigolon R, Monteiro I, Balardin J, Padilha E Front Pharmacol. 2024; 15:1338546.

PMID: 39224777 PMC: 11366779. DOI: 10.3389/fphar.2024.1338546.

Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru.

Otoya I, Valdiviezo N, Roque K, Morante Z, Vidaurre T, Neciosup S Ecancermedicalscience. 2024; 18:1708.

PMID: 39021543 PMC: 11254399. DOI: 10.3332/ecancer.2024.1708.

ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation.

Nicholas R, Scalfaro E, Dorsey R, Angehrn Z, Banhazi J, Brennan R Pharmacoecon Open. 2024; 8(5):755-764.

PMID: 38990487 PMC: 11362419. DOI: 10.1007/s41669-024-00493-8.

Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective.

Lei M, Li Q, ODay K, Meyer K, Wang A, Jun M Future Oncol. 2024; 20(29):2189-2201.

PMID: 38913826 PMC: 11508956. DOI: 10.1080/14796694.2024.2354157.

Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.

Heng J, Raman S, Wong Z, Beh V Daru. 2023; 32(1):67-76.

PMID: 37903943 PMC: 11087381. DOI: 10.1007/s40199-023-00485-9.

References

Rosenthal V, Guzman S, Migone O, Crnich C . The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysis. Am J Infect Control. 2003; 31(8):475-80. DOI: 10.1016/j.ajic.2003.03.002. View

Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S . Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012; 13(9):869-78. DOI: 10.1016/S1470-2045(12)70329-7. View

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B . Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2013; 53(2):192-201. DOI: 10.1177/0091270012436560. View

Bookbinder L, Hofer A, Haller M, Zepeda M, Keller G, Lim J . A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006; 114(2):230-41. DOI: 10.1016/j.jconrel.2006.05.027. View

Launay-Vacher V . An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs. Cancer Chemother Pharmacol. 2013; 72(6):1361-7. DOI: 10.1007/s00280-013-2289-4. View

Kruse G, Amonkar M, Smith G, Skonieczny D, Stavrakas S . Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008; 14(9):844-57. PMC: 10438104. DOI: 10.18553/jmcp.2008.14.9.844. View

. Preventing infections associated with indwelling intravascular access devices. Can Commun Dis Rep. 2001; 23 Suppl 8:i-iii, 1-32, i-iv, 1-16. View

Worth L, Brett J, Bull A, McBryde E, Russo P, Richards M . Impact of revising the National Nosocomial Infection Surveillance System definition for catheter-related bloodstream infection in ICU: reproducibility of the National Healthcare Safety Network case definition in an Australian cohort of infection.... Am J Infect Control. 2009; 37(8):643-8. DOI: 10.1016/j.ajic.2009.02.013. View

Boersma R, Schouten H . Clinical practices concerning central venous catheters in haematological patients. Eur J Oncol Nurs. 2010; 14(3):200-4. DOI: 10.1016/j.ejon.2009.12.005. View

10.

Frost G . Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007; 4(4):427-40. DOI: 10.1517/17425247.4.4.427. View

11.

Rule S, Collins G, Samanta K . Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014; 17(7):459-68. DOI: 10.3111/13696998.2014.914033. View

12.

Pettengell R, Davies A, Harvey V . Experience with an implantable venous access system for chemotherapy. N Z Med J. 1991; 104(915):284-5. View

13.

Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A . Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013; 14(10):962-70. DOI: 10.1016/S1470-2045(13)70383-8. View

14.

Vescia S, Baumgartner A, Jacobs V, Kiechle-Bahat M, Rody A, Loibl S . Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2007; 19(1):9-15. DOI: 10.1093/annonc/mdm272. View

15.

McKenzie F, Ellison-Loschmann L, Jeffreys M . Investigating reasons for socioeconomic inequalities in breast cancer survival in New Zealand. Cancer Epidemiol. 2010; 34(6):702-8. DOI: 10.1016/j.canep.2010.07.007. View